Can Congress Get 'Right to Try' Right?

Area of Science:

• Medical Ethics
• Drug Regulation
• Patient Advocacy

Background:

• The "right to try" movement advocates for terminally ill patients to access experimental drugs before FDA approval.
• Existing state-level right-to-try laws have seen limited utilization.
• Concerns exist regarding patient safety and the potential erosion of regulatory standards.

Purpose of the Study:

• To analyze the implications of a proposed federal right-to-try bill.
• To examine the arguments for and against expanded access to unapproved treatments.
• To assess the practical impact of right-to-try legislation.

Main Methods:

• Review of proposed federal legislation.
• Analysis of arguments from proponents and critics.
• Examination of data on the usage of state-level right-to-try laws.

Main Results:

• Federal legislation seeks to broaden access to experimental therapies for critically ill individuals.
• Critics express concerns about diminished Food and Drug Administration (FDA) oversight.
• Proponents highlight the burdensome nature of current FDA processes for patients with limited time.

Conclusions:

• The debate over right-to-try legislation involves balancing patient access with regulatory safety.
• The limited use of state laws suggests potential barriers or lack of demand.
• Further evaluation is needed to understand the real-world impact of federal right-to-try expansion.